Product Description
for Diabetic Neuropathic Pain (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01820715)
Mechanisms of Action: CSF Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Neuralgia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01820715 |
DA3030_DN_I (Version 3.4) | P1 |
Completed |
Neuralgia |
2013-04-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|